Umer Raffat

Stock Analyst at Evercore ISI Group

(0.98)
# 3,497
Out of 4,814 analysts
21
Total ratings
50%
Success rate
-11.49%
Average return

Stocks Rated by Umer Raffat

Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $17.55
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.65
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $3.99
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.22
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.79
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $27.05
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.25
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $13.64
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $4.08
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.26
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $32.77
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $11.12
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $2.84
Upside: -
Initiates: Outperform
Price Target: $48
Current: $0.65
Upside: +7,284.62%
Upgrades: Outperform
Price Target: n/a
Current: $277.29
Upside: -
Initiates: Outperform
Price Target: $48
Current: $6.21
Upside: +672.95%
Initiates: Buy
Price Target: n/a
Current: $102.02
Upside: -